Easton Pharmaceuticals

What Easton Pharmaceuticals does

Easton Pharmaceuticals is a Toronto, Canada-based specialty pharmaceutical company incorporated in 1997 and publicly listed on the OTC Pink market under the ticker EAPH. The company has historically described itself as designing topically-delivered therapeutic products, positioning within the small-cap dermatology and women's health niches typical of micro-cap pharma issuers. Its most material documented strategic action is the January 2017 acquisition of iBliss, which extended its specialty pharma footprint into a new product line for an undisclosed consideration.

The company's leadership consists of founder and Chairman John Easton and CFO Lee Hendelson, and it operates with an extremely lean headcount of 1–10 employees, consistent with a shell or holding-company structure rather than an active commercial operation. Publicly available revenue figures spanning 2014 to 2019 are internally inconsistent and implausibly large (rising into the hundreds of billions and trillions of dollars) for an entity of this size, indicating either data corruption, mismatched sourcing, or severe reporting deficiencies. The corporate website at eastonpharma.com is currently a parked domain-for-sale page with no corporate content, product information, or investor disclosures, which is a strong indicator that the entity is not actively operating its commercial or investor-facing functions. Based on available evidence, the company does not appear to be running an active commercial pharmaceutical business at present.

Name

Easton Pharmaceuticals

Website

https://eastonpharma.com

Company type

Private

Founded year

1997

Headcount range

1–10 employees

Short description

Easton Pharmaceuticals is a Toronto-based, OTC Pink-listed specialty pharmaceutical company (founded 1997, 1–10 employees) historically focused on topically-delivered therapeutics. Its primary web domain is currently parked for sale and no active commercial operations are evidenced.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industry

Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)

Keywords

• Specialty pharmaceuticals
• Topical therapeutics
• Pharmaceutical development
• Drug formulation
• Dermatological products

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Marketing or Sales, Technology or R&D

Core offering

Easton Pharmaceuticals is described in firmographic records as a specialty pharmaceutical company that designs, develops, and markets various topically therapeutic products. Note: the company's primary website (eastonpharma.com) is currently listed as a premium domain for sale and explicitly disclaims affiliation with any active company, product, service, or brand, so current operational product activity cannot be verified from the live web source.

Differentiator

Problem solved

Functional benefit

Products and services

• Topically Therapeutic Pharmaceutical Products

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves2 records

Expansion highlights1 record

Emerging players

• Mayne Pharma: Mayne Pharma is a smaller specialty pharma with a notable topical and dermatology franchise in the U.S., making it a relevant emerging player comp for a niche topical therapeutic company.
• Amneal Pharmaceuticals: Amneal is a U.S.-focused specialty and generics manufacturer with topical dosage-form capabilities, comparable in scale and category mix to a small specialty topical player.

Broad incumbents

• Sandoz (Novartis): Sandoz is a global leader in generic and specialty pharmaceuticals including topical dosage forms, providing a broad-incumbent comp for a small topical specialty pharma.
• Viatris (formerly Mylan): Viatris is a broad global specialty and generics pharmaceutical major with significant topical and dermatology product lines, comparable to Easton as a broad incumbent with overlapping therapeutic categories.
• Bausch Health (formerly Valeant): Bausch Health operates one of the largest dermatology/prescription-topical franchises globally, comparable as a broad incumbent with topical therapeutic exposure.

Direct peers

• Taro Pharmaceutical Industries: Taro specializes in topical dermatological generics and specialty pharmaceuticals, with a portfolio profile that closely mirrors Easton's stated topical therapeutic focus.
• Galderma: Galderma is the leading global specialty pharma company focused exclusively on dermatology and topical therapeutics, making it the closest direct comp to a topically-focused specialty pharma like Easton.
• Perrigo Company: Perrigo is a leading topical generics and OTC dermatology manufacturer, directly comparable to a small specialty pharma designing and marketing topical therapeutic products.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat1 record

Key risks5 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/easton-pharmaceuticals-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Easton Pharmaceuticals